X
No Ads. No Trackers. No Kidding! (Learn More)
Loading...
Thumbnail
Members of the Food and Drug Administration's vaccines advisory committee signaled an eagerness on Friday to authorize mix-and-match boosting of Covid-19... [Read More]
Frederic J. Brown/AFP via Getty Images ... [Read More]
Recommendation could undermine the advantage that the J&J vaccine had as a single-dose treatment over two-dose rivals. [Read More]
Trial results from Merck's oral Covid-19 antiviral dented the stocks of other biopharma firms that sell monoclonal antibody treatments for the disease,... [Read More]
Thumbnail
Food and Drug Administration drug rulings expected in the coming months could affect the stocks of big pharma companies like Pfizer and Eli Lilly, and... [Read More]
Advisory committee supports authorizing a third, smaller dose of Covid vaccine for people aged 18 to 64 at high risk of severe disease, or whose... [Read More]
Sarah Silbiger/Getty Images ... [Read More]
Advisory committee supports authorizing a third, smaller dose of Covid vaccine for people aged 18 to 64 at high risk of severe disease, or whose... [Read More]
Sarah Silbiger/Getty Images ... [Read More]
Analysts said that the results resolved near-term overhangs, and shifted the focus to next year. [Read More]
Shares of the major health insurer UnitedHealth Group leapt... [Read More]
The monoclonal antibody therapy, which is marketed under the name REGEN-COV, is currently available under an emergency-use authorization. [Read More]
Citi Research looks into safety concerns about Merck's antiviral molnupiravir, and says the drug should still get approved by the Food and Drug Administration. [Read More]
The results of a Phase 2 trial of the vaccine "are positive signals" for the coming Phase 3 trial, wrote SVB Leerink's Geoffrey Porges. [Read More]
The results of a Phase 2 trial of the vaccine "are positive signals" for the coming Phase 3 trial, wrote SVB Leerink's Geoffrey Porges. [Read More]
CureVac is halting development of its first messenger RNA-based Covid-19 vaccine. The news triggered a dive in the stock. [Read More]
CureVac is halting development of its first messenger RNA-based Covid-19 vaccine. The news triggered a dive in the stock. [Read More]
CureVac said early Tuesday it was halting development of its first messenger RNA-based Covid-19 vaccine, and would instead... [Read More]
Committee members also will hear a presentation on a so-called mix-and-match booster, or a dose of a vaccine different from the original one. [Read More]
Johnson & Johnson stock is up 1.8% this year. Here, a syringe filled with the company's Covid-19 vaccine. ... [Read More]
Loading...
Save As
Preview
Preview